Tier A · Established human benefit
Bremelanotide (PT-141)
A centrally acting peptide with a validated human sexual-health indication.
Why researchers care
Potential human relevance
- Improved sexual desire in appropriately selected premenopausal women with acquired generalized HSDD
- Reduced distress related to low sexual desire in pivotal trials
- Acts through central melanocortin pathways rather than local blood-flow mechanisms
What the human evidence says
Evidence, not extrapolation
Bremelanotide is FDA-approved for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. The approval does not extend to general libido enhancement in every population.
How to think about it
The Yooper Peptides take
It demonstrates that peptide signaling can influence central motivation and desire pathways—not only metabolism or tissue repair.
Primary / authoritative reading